RecruitingNot ApplicableNCT02740634
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
Sponsor
Mayo Clinic
Enrollment
60 participants
Start Date
May 1, 2016
Study Type
INTERVENTIONAL
Conditions
Summary
This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.
Eligibility
Min Age: 21 YearsMax Age: 80 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called C-11 PiB and a drug called F-18 AV 1451 for people with alzheimer disease, alzheimer disease, early onset, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 80 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGF-18 AV 1451
Tau binding agent
DRUGC-11 PiB
Amyloid binding agent
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02740634
Related Trials
Digital Dementia Registry Bavaria (digiDEM Bayern): a Multicentre, Prospective, Longitudinal Register Study Including People With Mild Cognitive Impairment and Dementia as Well as Their Family Caregivers
NCT0772170112 locations
AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
NCT071589055 locations
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
NCT076334705 locations
A Study of LY3439539 in Participants With Alzheimer's Disease
NCT075983709 locations
Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)
NCT077207651 location